GenDx established in 2005 is celebrating her 10^th Anniversary

The 1^st of March 2005, GenDx was founded by Erik Rozemuller, Wietse Mulder and Oscar Schoots (representing UMC participaties B.V.) and therefore we celebrate this year our 10^th anniversary.

Starting with 4 employees and a software program written in DOS, much has changed over the last 10 years. Nowadays, the company has about 35 employees allowing GenDx to be able to support HLA typing laboratories with the newest technologies and optimized workflows for HLA typing. So, do we offer a unique approach for Sanger based strategies, and have we expanded this recently with new solutions employing Next Generation Sequencing approaches.

GenDx believes that progress can be best achieved through partnerships, of with ultimo the patient may benefit the most. Since the onset of the company we are collaborating with numerous laboratories worldwide, several other suppliers and also various local distributors. We value partnerships as crucial, without letting go our independent position and having a strong focus on education and training of the end-users.

We believe that by giving end-users access to better tools and enhance their typing skills, patients and donors can be typed more accurate, allowing better patient-donor matching, enhancing thereby the success rate of transplantations.

In 2013, GenDx founders have taken a new initiative and have started together with the American Doug Bost the company KimerDx BV. This initiative is focussed on testing methods to follow the engraftment by accurate chimerism monitoring post-transplantation. With this first step outside the HLA typing field we believe we can now even better support laboratory and clinical workers active in the field of transplantation.

At GenDx we believe that our main task is to support customers, providing excellent products and service, but also to create a stimulating environment for all employees. The close knit management team aims to create a working atmosphere with has ample room for personal development, job satisfaction and we use direct and transparent way of communications. The absence of framed departments creates flexibility and the option to engage in projects that suit personal talents and ambitions.

Looking ahead GenDx will continue to use its expertise and knowledge to develop and market innovative, certified diagnostic products that will provide crucial information for patient-tailored treatments in and beyond transplantation therapy.